Leerink Swann reaffirmed their positive rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report sent to investors on Wednesday, The Fly reports. Leerink Swann currently has a $29.00 target price on the stock, up from their prior target price of $20.00.
Other equities research analysts have also issued reports about the company. Deutsche Bank assumed coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They issued a buy rating and a $42.00 target price on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $65.00 target price (up from $50.00) on shares of Deciphera Pharmaceuticals in a research report on Wednesday. Piper Jaffray Companies increased their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an overweight rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. BidaskClub raised Deciphera Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 2nd. Finally, Zacks Investment Research raised Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 price target for the company in a research note on Monday, August 5th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of Buy and an average target price of $47.90.
Shares of NASDAQ DCPH opened at $37.00 on Wednesday. Deciphera Pharmaceuticals has a 1-year low of $18.55 and a 1-year high of $42.99. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $23.38 and its two-hundred day moving average price is $24.40.
In related news, insider Daniel Lee Flynn sold 148,107 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $40.92, for a total value of $6,060,538.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Douglas Taylor sold 22,500 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $40.77, for a total value of $917,325.00. The disclosure for this sale can be found here. Insiders sold a total of 185,607 shares of company stock valued at $7,536,409 in the last quarter. 7.02% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in DCPH. Bank of Montreal Can acquired a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at $28,000. BNP Paribas Arbitrage SA boosted its position in shares of Deciphera Pharmaceuticals by 61,033.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock valued at $43,000 after purchasing an additional 1,831 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter valued at $64,000. JPMorgan Chase & Co. boosted its position in shares of Deciphera Pharmaceuticals by 89.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock valued at $95,000 after purchasing an additional 1,913 shares during the period. Finally, Morgan Stanley boosted its position in shares of Deciphera Pharmaceuticals by 214.8% in the 2nd quarter. Morgan Stanley now owns 7,864 shares of the company’s stock valued at $177,000 after purchasing an additional 5,366 shares during the period. Institutional investors and hedge funds own 59.10% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.